291 related articles for article (PubMed ID: 34389849)
1. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.
Michel L; Helfrich I; Hendgen-Cotta UB; Mincu RI; Korste S; Mrotzek SM; Spomer A; Odersky A; Rischpler C; Herrmann K; Umutlu L; Coman C; Ahrends R; Sickmann A; Löffek S; Livingstone E; Ugurel S; Zimmer L; Gunzer M; Schadendorf D; Totzeck M; Rassaf T
Eur Heart J; 2022 Jan; 43(4):316-329. PubMed ID: 34389849
[TBL] [Abstract][Full Text] [Related]
2. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
3. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment.
Gergely TG; Kucsera D; Tóth VE; Kovács T; Sayour NV; Drobni ZD; Ruppert M; Petrovich B; Ágg B; Onódi Z; Fekete N; Pállinger É; Buzás EI; Yousif LI; Meijers WC; Radovits T; Merkely B; Ferdinandy P; Varga ZV
Br J Pharmacol; 2023 Mar; 180(6):740-761. PubMed ID: 36356191
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
[TBL] [Abstract][Full Text] [Related]
6. PD1 Deficiency Modifies Cardiac Immunity during Baseline Conditions and in Reperfused Acute Myocardial Infarction.
Michel L; Korste S; Spomer A; Hendgen-Cotta UB; Rassaf T; Totzeck M
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886878
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart.
Korste S; Settelmeier S; Michel L; Odersky A; Stock P; Reyes F; Haj-Yehia E; Anker MS; Grüneboom A; Hendgen-Cotta UB; Rassaf T; Totzeck M
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047026
[TBL] [Abstract][Full Text] [Related]
8. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
9. [Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine
in Attenuating the Related Mortality in Mice].
Chen Z; Wang M; Gao S; Guo H; Wang G; Zhou G
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):394-403. PubMed ID: 34157799
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
11. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.
Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S
Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
Gault A; Anderson AE; Plummer R; Stewart C; Pratt AG; Rajan N
Br J Dermatol; 2021 Aug; 185(2):263-271. PubMed ID: 33393076
[TBL] [Abstract][Full Text] [Related]
13. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
[TBL] [Abstract][Full Text] [Related]
14. Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction.
Michel L; Ferdinandy P; Rassaf T
Curr Heart Fail Rep; 2024 Jun; 21(3):214-223. PubMed ID: 38430308
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity from immune checkpoint inhibitors.
Michel L; Rassaf T; Totzeck M
Int J Cardiol Heart Vasc; 2019 Dec; 25():100420. PubMed ID: 31517036
[TBL] [Abstract][Full Text] [Related]
16. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
Hajem S; Ederhy S; Champiat S; Troalen F; Nolin-Lapalme A; Berhoune M; Cauquil C; Martin-Romano P; Baldini C; Laparra A; Vuagnat P; Hollebecque A; Mateus C; Besse B; Naltet C; Robert C; Marabelle A; Massard C; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 157():383-390. PubMed ID: 34571335
[TBL] [Abstract][Full Text] [Related]
17. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.
Almutairi AR; Slack M; Erstad BL; McBride A; Abraham I
Ther Adv Drug Saf; 2021; 12():2042098621991279. PubMed ID: 33796257
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Schwartzman G; Simpson MM; Jones R; Schiavone K; Coffman M; Meyerle J
Cutis; 2020 Jun; 105(6):E9-E12. PubMed ID: 32716997
[TBL] [Abstract][Full Text] [Related]
19. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]